IXICO plc

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:18 2025-12-08 EST			5-day change	1st Jan Change
10.75 ^GBX	0.00%		-2.27%	-8.51%

12-01	IXICO plc Announces Scientific Advisory Board Appointments, Effective December 1, 2025	CI
11-17	Ixico wins GBP3.7 million deal to support Huntington's Disease trial	AN

Ixico Bags Imaging Services Deal with US Client

Published on 12/10/2024 at 08:08 am EST - Modified on 12/10/2024 at 08:54 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about IXICO plc

12-01	IXICO plc Announces Scientific Advisory Board Appointments, Effective December 1, 2025	CI
11-17	Ixico wins GBP3.7 million deal to support Huntington's Disease trial	AN
11-17	AIM WINNERS & LOSERS: OptiBiotix and Ixico rise on deal wins	AN
11-17	Uncertain trade as belated US jobs data looms	AN
11-17	Ixico announces phase 3 clinical trial contract win worth over 3.5 mln stg over four years	RE
11-17	IXICO plc Announces Global Phase 3 Clinical Trial Contract Win Worth over £3.5 Million	CI
10-16	Anglo Asian copper production rises, backs guidance	AN
10-16	Earnings Flash (IXI.L) Ixico Reports FY25 Revenue GBP6.5M	MT
10-15	Ixico Wins New Deal, Contract Extension Totaling GBP1 Million	MT
10-15	Ixico plc announces new contract and extension worth total of u1.2 million	RE
10-15	Ixico plc Announces New Blood Based Biomarker Contract Win and Contract Extension Worth A Total of £1.2 Million	CI
08-12	Ixico wins neuroimaging contracts worth over GBP1 million	AN
08-12	Ixico Wins Two New Commercial Neuroimaging Contracts	MT
08-12	IXICO signs £1.3 million neuroimaging contracts	RE
08-12	IXICO plc Announces Global Clinical Trial Contract Wins in Alzheimer's Disease and Friedreich's Ataxia	CI
07-22	Flowtech wins deals; SpaceandPeople revenue climbs	AN
07-22	Global Alzheimer?s Platform Foundation Announces Strategic Collaboration and Partnership with IXICO for the Transformative Bio-Hermes-002 Study	CI
07-22	Ixico to Acquire Full Data Rights to Global Alzheimer's Platform Foundation's New Study	MT
07-22	Ixico partners with Global Alzheimer's Platform Foundation	RE
07-17	FTSE 100 closes up despite "harsh" UK jobs data	AN
07-17	FTSE 100 closes up despite "harsh" UK jobs data	AN
07-17	Ixico expects return to profitability as annual revenue set to rise	AN
07-17	Ixico expects revenue growth will continue into 2026	RE
07-17	Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2025	CI
06-10	Ixico cheers FDA approval for contractor Fujirebio's Alzheimer's test	AN

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-12-08 - Q4 2025 Earnings Release

More about the company